Allergy Therapeutics (AGY)

 

Latest News

Allergy Therapeutics gets approval for PQ Grass trial

Allergy Therapeutics has received approval for a phase II clinical trial of investigating the dosing of PQ Grass, an ultra-sho...

Approval for PQ Grass Phase II trial

RNS Number: 9660Q Allergy Therapeutics PLC 18 September 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Approval of clinical trial application for PQ Grass Phase II trial - Trial aimed at determining optimal dose of an MPL-adjuvanted, modified grass allergy vaccine - 18 September 2017 Allergy Therapeutics plc (AIM:AGY), the fully integra...

Allergy Therapeutics expands R&D and clinical team

Allergy Therapeutics has announced new senior appointments and expansion of the R&D and clinical team in line with th...

Expansion of Clinical Development and R&D teams

RNS Number: 2846Q Allergy Therapeutics PLC 11 September 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Expansion of Clinical Development and R&D teams - Key appointments reflect Group's commitment to EU and US strategy for product development - 11 September 2017 Allergy Therapeutics plc (AIM:AGY), the fully integrated special...

All News

DateHeadlineSource
16-12-14Allergy Therapeutics appoints adviser StockMarketWire
16-12-14Change of AdviserRNS
19-11-14Allergy Therapeutics resolutions passed at AGMStockMarketWire
19-11-14Result of AGMRNS
18-11-14Allergy strengthens its board StockMarketWire
18-11-14Appointment of a Non-Executive DirectorRNS
05-11-14Grant of OptionsRNS
04-11-14Appointment of Head of Clinical ScienceRNS
23-10-14Annual Report and AccountsRNS
08-10-14Allergy Therapeutics director steps down StockMarketWire
08-10-14Directorate ChangeRNS
01-10-14Total Voting RightsRNS
30-09-14Amendment of 2012 Loan Note termRNS
29-09-14Holding(s) in CompanyRNS
24-09-14Exercise of OptionsRNS
24-09-14Annual Report and AccountsRNS
22-09-14Profits improve at Allergy TherapeuticsStockMarketWire
22-09-14Final ResultsRNS
04-09-14Shareholder updateRNS
27-08-14Allergy Therapeutics schedules results announcementStockMarketWire
24-07-14Allergy Therapeutics revenues upStockMarketWire
24-07-14Notice of Results and Trading UpdateRNS
17-07-14Holding(s) in CompanyRNS
30-04-14Allergy Therapeutics' licence renewedStockMarketWire
30-04-14Worthing Facility Licence RenewalRNS
25-04-14Director/PDMR ShareholdingRNS
17-04-14Allergy Therapeutics convertible loan extendedStockMarketWire
17-04-14Extension of Convertible Loan NoteRNS
02-04-14Holding(s) in CompanyRNS
24-03-14Allergy grows profits StockMarketWire
24-03-14Half Yearly ReportRNS
17-03-14Notice of ResultsRNS
12-03-14Shareholder updateRNS
19-02-14Health Canada approves Allergy CTA submission StockMarketWire
19-02-14Health Canada approves submission of CTARNS
11-02-14Holding(s) in CompanyRNS
27-01-14Allergy Therapeutics study results publishedStockMarketWire
27-01-14Results published in highly respected journalRNS
14-01-14Allergy Therapeutics revenues up 12%StockMarketWire
14-01-14Trading Update and Notice of ResultsRNS

RSS feeds

  • Editorial news feed for LSE:AGY Editorial
  • Regulatory news feed for LSE:AGY Regulatory